Literature DB >> 932021

Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity.

T A Krenitsky, J V Tuttle, G W Koszalka, I S Chen, L M Beacham, J L Rideout, G B Elion.   

Abstract

Kinetic constants were determined for 34 nucleoside substrates of deoxycytidine kinase (EC 2.7.1.74) from calf thymus. Substrate efficiency was assessed by the ratio of Vmax to Km. Inhibition constants were determined for 61 nonsubstrate nucleosides or nucleoside analogues. The enzyme was relatively specific for the pentose moiety of nucleoside substrates. beta-D-2'-Deoxyribonucleosides were more efficient substrates than the corresponding beta-D-arabinonucleosides. Unexpectedly, the L isomer of the beta-arabinonucleoside of cytosine was a more efficient substrate than was the D isomer. beta-Cytidine and beta-5-azacytidine were the only beta-D-ribonucleosides studied that had detectable substrate activity. alpha-Cytidine was an inhibitor but not a substrate. Nucleosides containing a variety of sugar moieties other than those mentioned above did not have detectable substrate activity. The enzyme was relatively nonspecific for the base moiety of nucleoside substrates. 2'-Deoxyribonucleosides of a variety of pyrimidines, purines, and other heterocycles were substrates. Cytosine was the most preferred pyrimidine moiety. 5-Substitution, except with fluorine, decreased substrate efficiency with nucleosides of cytosine or uracil. 2-Fluoradenine was the most preferred purine moiety. The effects of various purine ring substituents were interdependent. Nucleosides containing bulky, hydrophobic substituents on either the base or the pentose moiety had no substrate activity but were relatively potent competitive inhibitors. This suggested the presence of a hydrophobic region on the surface of the enzyme near the active site.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 932021

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.

Authors:  B Ullman; L J Gudas; S M Clift; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

2.  6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus.

Authors:  D R Averett; G W Koszalka; J A Fyfe; G B Roberts; D J Purifoy; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

4.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  Antagonism of the cytotoxic but not antiviral effects of ara-sangivamycin by adenosine.

Authors:  G M Birch; S H Krawczyk; L B Townsend; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Anabolic pathway of 6-methoxypurine arabinoside in cells infected with varicella-zoster virus.

Authors:  P de Miranda; T C Burnette; K K Biron; R L Miller; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Authors:  S C Stanat; J E Reardon; A Erice; M C Jordan; W L Drew; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

8.  Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function.

Authors:  E W Gelfand; J J Lee; H M Dosch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

9.  Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.

Authors:  V Gandhi; L E Robertson; M J Keating; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.